JXL069 is an experimental drug originally developed at the University of California, Los Angeles (UCLA), that functions as a potent and highly selective mitochondrial pyruvate carrier (MPC) inhibitor, effectively disrupting the regulated import of pyruvate into mitochondria, altering cellular energy metabolism, and demonstrating promising preclinical efficacy as a metabolic modulator in androgenetic alopecia through mechanistic validation in animal model studies.

MPC:~40-50 nM

In cellular assays, JXL069 inhibits MPC activity with high potency, exhibiting an IC₅₀ in the nanomolar range (approximately 40-50 nM) [1].

In in vivo dermatological models using C57BL/6 mice, JXL069 demonstrates the ability to induce hair growth via topical application. When applied to mice in the telogen phase (characterized by pink skin), the compound triggers a rapid transition to the anagen phase (characterized by dark skin pigmentation). Treated mice exhibit visible hair regrowth significantly faster than vehicle-treated controls, with effects comparable to or potentially exceeding standard treatments like minoxidil [2].